Last-Resort radiation treatment shows promise for rare childhood cancers
NCT ID NCT01850888
First seen Nov 10, 2025 · Last updated May 23, 2026 · Updated 26 times
Summary
This study offered a radioactive drug called 131I-MIBG to 15 people with advanced neuroblastoma or pheochromocytoma who had run out of standard options. The goal was to see if it could ease symptoms and shrink tumors, while tracking side effects. Participants received a dose based on their stem cell health and bone marrow involvement.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED NEUROBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Minnesota Masonic Cancer Center
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.